Rajeev Saggar
Chief Tech/Sci/R&D Officer bij LIQUIDIA CORPORATION
Vermogen: 3 M $ op 31-03-2024
Profiel
Rajeev Saggar is currently the Chief Medical Officer at Liquidia Corp.
Prior to this, he was the Vice President of Clinical Development at Theravance Biopharma US, Inc. from 2021 to 2022.
He also served as the Medical Director for Pulmonary Hypertension & Fibrosis at The Banner-University Medical Center.
Dr. Saggar holds a doctorate degree from the University of California, Irvine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LIQUIDIA CORPORATION
0.28% | 19-04-2024 | 211 672 ( 0.28% ) | 3 M $ | 31-03-2024 |
Actieve functies van Rajeev Saggar
| Bedrijven | Functie | Begin |
|---|---|---|
| LIQUIDIA CORPORATION | Chief Tech/Sci/R&D Officer | 18-07-2022 |
Eerdere bekende functies van Rajeev Saggar
| Bedrijven | Functie | Einde |
|---|---|---|
Theravance Biopharma US, Inc.
 Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01-07-2022 |
| The Banner-University Medical Center | Corporate Officer/Principal | - |
Opleiding van Rajeev Saggar
| University of California, Irvine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Theravance Biopharma US, Inc.
Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Commercial Services |
| Liquidia Corp. |
